ORI Capital, Longitude Capital and Decheng Capital led a $120m Series E funding round in CG Oncology.

ORI Capital, a venture capital firm, Longitude Capital, a healthcare venture capital firm, and Decheng Capital, an investment firm that provides capital and strategic support to early stage life science companies, led a $120m Series E funding round in CG Oncology, an oncolytic immunotherapy company, with participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge Group and Sirona Capital. “We have strong conviction in CG Oncology which continues to generate compelling data to develop potential bladder-sparing innovative therapeutics for patients suffering from bladder cancer. We’ve been strong supporters of the CG Oncology team from an early stage by leading the Series C round, and we are particularly proud to co-lead this round with Longitude Capital and Decheng Capital, as we see tremendous potential for CG0070 to be a game changer for patients with NMIBC,” Simone Song, ORI Capital Founder and Senior Partner.